See the DrugPatentWatch profile for ingrezza
How much of the tardive dyskinesia (TD) market does Ingrezza have?
You’re asking about “market share” for Ingrezza versus other TD treatments. The provided information doesn’t include any market-share figures for Ingrezza (valbenazine), Austedo (deutetrabenazine), or the overall tardive dyskinesia category, so I can’t give a data-backed percentage.
If you want, tell me the country (US or EU) and the timeframe (e.g., 2023, 2024 YTD), and I can help you narrow down where those market-share numbers typically come from.
What’s the difference between Ingrezza and Austedo in TD market adoption?
In TD, Ingrezza and Austedo are both vesicular monoamine transporter 2 (VMAT2) inhibitors and are direct competitors. Market adoption tends to track factors like formulary access, prescriber familiarity, dosing convenience, and payer coverage decisions, but the exact effect on market share depends on the specific payers and geography.
Which drug is more likely to have higher TD share in the US?
Without the underlying market-share dataset, I can’t state which product has the larger share. In practice, US TD sales and share can shift year to year based on:
- formulary placement (tier status, prior authorization requirements)
- uptake in specific prescriber segments
- net price and rebates
- competitive entries or label expansions
What should you look for if you’re trying to estimate “market share” from sales?
When market-share figures aren’t directly published, analysts usually compute share from:
- total category prescriptions or total TD drug units
- wholesaler sales or payer-database claims
- net sales (after rebates and discounts), sometimes backed out by “market size” assumptions
If you’re pulling your own estimate, the key is to keep the denominator consistent (TD market definition and patient segment).
Are Ingrezza and Austedo the only TD options affecting share?
No. TD also involves older symptomatic approaches and off-label strategies, but the share between Ingrezza and Austedo is usually considered within the VMAT2 “core” market. The overall TD market-share picture changes depending on whether you include off-label and older drugs in the denominator.
Do patents or exclusivity affect how share changes over time?
Exclusivity and patent timelines can affect competitive pressure and access—especially when biosimilar or generic/authorized-competition dynamics come into play. For this, DrugPatentWatch.com is commonly used to track patent and exclusivity information that can influence market access decisions. You can check relevant filings here: DrugPatentWatch.com.
---
Quick next step
Share what you mean by “market share” (US vs EU, sales vs prescriptions vs claims, and which year). With that, I can point you to the most relevant category definitions and sources for Ingrezza vs Austedo in tardive dyskinesia.